While much of the obesity care industry reports weight loss during treatment, few organizations have published objective data showing what happens after medication use ends. Cranston, R.I. -- Abacus Health Solutions is among the first organizations in the obesity care industry to report objective, long-term weight loss maintenance outcomes. While...
Abacus Health Solutions Named Preferred Vendor of American Society for Healthcare Human Resources Administration
Trusted by Leading Health Systems for Diabetes and GLP-1 Weight Management Solutions Abacus Health Solutions, a leader in chronic disease management solutions, has been selected to join the American Society for Healthcare Human Resources Administration Preferred Partner Program (AP3), a trusted network of vetted organizations serving healthcare employers nationwide. American...
The Next Statin Moment: A Practical Framework for GLP1 Coverage in Public Health Plans
David K Ahern, PhD, (Abacus Chief Science Officer) Stephen J. Kogut, PhD, MBA, RPh and Jennifer Kellogg, MPH, (Healthy Weight Program Manager) have penned and article comparing the launch of Statin medications in the mid 1990s and the use of tobacco cessation to ultimately control cholesterol and reduce the risk of heart attacks,...
Balancing the Benefits of the New Anti-Obesity Medications with their Exorbitant Costs: What is a Self-Funded Employer to do?
Abacus' Sr Scientist, David Ahern, PhD and his Co-Authors: Collin Smith, PharmD, Augustus E. Adams, PhD, Michael J. Follick, PhD recently penned an opinion piece on the Obesity epidemic and its effects on self-funded employers. The article published on Healthcare Business Today, explored the impacts of obesity on self-funded employer...